MEDFORD, NY / ACCESSWIRE / November 9, 2016 / Chembio Diagnostics, Inc. CEMI will host a conference call and live webcast to discuss the results of the third quarter 2016, to be held Thursday, November 10, 2016 at 10:00 AM Eastern Time.
Live Event Information
To participate, connect approximately 5 to 10 minutes before the beginning of the event.
- Date, Time: November 10, 2016 at 10:00 AM ET
- Toll Free: 877-407-0778
- International: 201-689-8565
- Live Webcast: www.investorcalendar.com/IC/CEPage.asp?ID=175428 or www.chembio.com
Replay Information
The replay will be available beginning approximately 2 hours after the completion of the live event ending at midnight Eastern on November 17, 2016.
- Toll Free: 877-481-4010
- International: 919-882-2331
- Replay ID#: 10129
- Webcast: www.investorcalendar.com or www.chembio.com
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay and SURE CHECK® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. SURE CHECK® HIV 1/2 Assay previously has been sold in the U.S. exclusively as Clearview® Complete HIV 1/2 Assay. Outside the U.S., Chembio markets its SURE CHECK® HIV 1/2 Assays through distributors.
Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.
Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.
SOURCE: Investor Calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.